Identification and Characterization of Novel, Naturally Processed Measles Virus Class II HLA-DRB1 Peptides

ABSTRACT Previously, we identified a naturally processed and presented measles virus (MV) 19-amino-acid peptide, ASDVETAEGGEIHELLRLQ (MV-P), derived from the phosphoprotein and eluted from the human leukocyte antigen (HLA) class II molecule by using mass spectrometry. We report here the identification of a 14-amino-acid peptide, SAGKVSSTLASELG, derived from the MV nucleoprotein (MV-N) bound to HLA-DRB1*0301. Peripheral blood mononuclear cells (PBMC) from 281 previously vaccinated measles-mumps-rubella II (MMR-II) subjects (HLA discordant) were studied for peptide recognition by T cells. Significant gamma interferon (IFN-γ) responses to MV-P and MV-N peptides were observed in 55.9 and 15.3% of subjects, respectively. MV-P- and MV-N-specific interleukin-4 (IL-4) responses were detected in 19.2 and 23.1%, respectively, of PBMC samples. Peptide-specific cytokine responses and HLA-DRB1 allele associations revealed that, for the MV-P peptide, the allele with the strongest association with both IFN-γ (P = 0.02) and IL-4 (P = 0.03) secretion was DRB1*0301. For MV-N, the allele with the strongest association with IFN-γ secretion was DRB1*1501 (P = 0.04), and the alleles with the strongest associations with IL-4 secretion were DRB1*1103 and DRB1*1303 (P = 0.01). These results indicate that HLA class II MV proteins can be processed, presented, and identified, and the ability to generate cell-mediated immune responses can be demonstrated. This information is promising for new vaccine design strategies with peptide-based vaccines.

[1]  E. Norrby,et al.  Monoclonal antibodies against five structural components of measles virus , 2005, Archives of Virology.

[2]  Heidemarie Neitzel,et al.  A routine method for the establishment of permanent growing lymphoblastoid cell lines , 1986, Human Genetics.

[3]  S. Naylor,et al.  Naturally processed measles virus peptide eluted from class II HLA-DRB1*03 recognized by T lymphocytes from human blood. , 2003, Virology.

[4]  C. Muller,et al.  The rationale of a peptide-conjugate vaccine against measles. , 2003, Vaccine.

[5]  Measles : Not just another viral exanthem , 2003 .

[6]  Stuart M. Brown,et al.  Rare, structurally homologous self-peptides promote thymocyte positive selection. , 2002, Immunity.

[7]  T. Hodge,et al.  Discordance at human leukocyte antigen-DRB3 and protection from human immunodeficiency virus type 1 transmission. , 2002, The Journal of infectious diseases.

[8]  A. Grañena,et al.  Frequency of HLA-DPB1 disparities detected by reference strand-mediated conformation analysis in HLA-A, -B, and -DRB1 matched siblings. , 2002, Human immunology.

[9]  J. Ernerudh,et al.  Detection of spontaneous and antigen-induced human interleukin-4 responses in vitro: comparison of ELISPOT, a novel ELISA and real-time RT-PCR. , 2002, Journal of immunological methods.

[10]  R. Vierkant,et al.  Identification of an association between HLA class II alleles and low antibody levels after measles immunization. , 2001, Vaccine.

[11]  W. Bellini,et al.  Induction of cytokine mRNA in peripheral blood mononuclear cells of infants after the first dose of measles vaccine. , 2001, Vaccine.

[12]  P. Roholl,et al.  A measles virus glycoprotein-derived human CTL epitope is abundantly presented via the proteasomal-dependent MHC class I processing pathway. , 2001, The Journal of general virology.

[13]  E. Unanue,et al.  Quantitation of Lysozyme Peptides Bound to Class II MHC Molecules Indicates Very Large Differences in Levels of Presentation1 , 2001, The Journal of Immunology.

[14]  Stephen Naylor,et al.  The role of mass spectrometry in vaccine development. , 2001, Vaccine.

[15]  R. Wahl,et al.  Towards defining the urinary proteome using liquid chromatography‐tandem mass spectrometry I.Profiling an unfractionated tryptic digest , 2001, Proteomics.

[16]  John Sidney,et al.  HLA-DR-Promiscuous T Cell Epitopes from Plasmodium falciparum Pre-Erythrocytic-Stage Antigens Restricted by Multiple HLA Class II Alleles1 2 , 2000, The Journal of Immunology.

[17]  C. Herberts,et al.  A single naturally processed measles virus peptide fully dominates the HLA‐A*0201‐associated peptide display and is mutated at its anchor position in persistent viral strains , 2000, European journal of immunology.

[18]  K. E. El Kasmi,et al.  Neutralization of measles virus wild-type isolates after immunization with a synthetic peptide vaccine which is not recognized by neutralizing passive antibodies. , 2000, The Journal of general virology.

[19]  W. Bellini,et al.  Comparison of L proteins of vaccine and wild-type measles viruses. , 1999, The Journal of general virology.

[20]  G. Poland.  Immunogenetic mechanisms of antibody response to measles vaccine: the role of the HLA genes. , 1999, Vaccine.

[21]  M F del Guercio,et al.  Several common HLA-DR types share largely overlapping peptide binding repertoires. , 1998, Journal of immunology.

[22]  W. Bellini,et al.  Use of synthetic peptides to identify measles nucleoprotein T-cell epitopes in vaccinated and naturally infected humans. , 1997, Virology.

[23]  D. Kirschmann,et al.  Naturally processed peptides from rheumatoid arthritis associated and non-associated HLA-DR alleles. , 1995, Journal of immunology.

[24]  R. Lal,et al.  Human T-lymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immunogenicity and overcome genetic restriction , 1995, Journal of virology.

[25]  V. ter meulen,et al.  Gamma interferon is a major mediator of antiviral defense in experimental measles virus-induced encephalitis , 1995, Journal of virology.

[26]  C. Partidos,et al.  Protection against morbillivirus-induced encephalitis by immunization with a rationally designed synthetic peptide vaccine containing B- and T-cell epitopes from the fusion protein of measles virus , 1995, Journal of virology.

[27]  F. Cutts,et al.  Successes and failures in measles control. , 1994, The Journal of infectious diseases.

[28]  S. Matsushita,et al.  Allele specificity of structural requirement for peptides bound to HLA- DRB1*0405 and -DRB1*0406 complexes: implication for the HLA-associated susceptibility to methimazole-induced insulin autoimmune syndrome , 1994, The Journal of experimental medicine.

[29]  R. Jacobson,et al.  Failure to reach the goal of measles elimination. Apparent paradox of measles infections in immunized persons. , 1994, Archives of internal medicine.

[30]  W. Bellini,et al.  Comparison of sequences of the H, F, and N coding genes of measles virus vaccine strains. , 1994, Virus research.

[31]  V. Gnau,et al.  Natural peptide ligand motifs of two HLA molecules associated with myasthenia gravis. , 1993, International immunology.

[32]  D. Gerlier,et al.  Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus , 1993, Journal of virology.

[33]  D. Griffin,et al.  Differential CD4 T cell activation in measles. , 1993, The Journal of infectious diseases.

[34]  F. Sinigaglia,et al.  Promiscuous and allele-specific anchors in HLA-DR-binding peptides , 1993, Cell.

[35]  V. ter meulen,et al.  Differential induction of cytokines by primary and persistent measles virus infections in human glial cells. , 1993, Virology.

[36]  J. Strominger,et al.  The dichotomy of peptide presentation by class I and class II MHC proteins. , 1993, Chemical immunology.

[37]  William Arbuthnot Sir Lane,et al.  Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles , 1993, The Journal of experimental medicine.

[38]  D. Griffin,et al.  Changes in cytokine production after measles virus vaccination: predominant production of IL-4 suggests induction of a Th2 response. , 1993, Clinical immunology and immunopathology.

[39]  J. Sidney,et al.  DRB1*0301 molecules recognize a structural motif distinct from the one recognized by most DR beta 1 alleles. , 1992, Journal of immunology.

[40]  W. Bellini,et al.  Genetic variability of the glycoprotein genes of current wild-type measles isolates. , 1992, Virology.

[41]  C. Partidos,et al.  Prediction and identification of a T cell epitope in the fusion protein of measles virus immunodominant in mice and humans. , 1990, The Journal of general virology.

[42]  P. Cresswell,et al.  High-affinity binding of an influenza hemagglutinin-derived peptide to purified HLA-DR. , 1990, Journal of immunology.

[43]  R. Klausner,et al.  Class II MHC molecules can use the endogenous pathway of antigen presentation , 1990, Nature.

[44]  Antonio Lanzavecchia,et al.  Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells , 1989, European journal of immunology.

[45]  Eric O Long,et al.  HLA class II-restricted presentation of cytoplasmic measles virus antigens to cytotoxic T cells , 1989, Journal of virology.

[46]  A. Trzeciak,et al.  A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules , 1988, Nature.

[47]  Eric O Long,et al.  Structural model of HLA-DR1 restricted T cell antigen recognition , 1988, Cell.

[48]  Eric O Long,et al.  Recognition of intracellular measles virus antigens by HLA class II-restricted measles virus-specific cytotoxic T lymphocytes , 1987, Journal of Neuroimmunology.

[49]  E. Norrby,et al.  Monoclonal antibodies against five structural components of measles virus. I. Characterization of antigenic determinants on nine strains of measles virus. , 1983, Virology.

[50]  L. Lampson,et al.  Two populations of Ia-like molecules on a human B cell line. , 1980, Journal of immunology.

[51]  F. Ennis,et al.  Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. , 1977, The Journal of pediatrics.